Fontes, Magda S. C.
Dingemanse, Jasper
Halabi, Atef
Tomaszewska-Kiecana, Monika
Sidharta, Patricia N.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
https://doi.org/10.1038/s41598-022-22470-z
Funding for this research was provided by:
Idorsia Pharmaceuticals Ltd, Switzerland
Article History
Received: 23 March 2022
Accepted: 14 October 2022
First Online: 9 November 2022
Competing interests
: M.S.C.F., J.D., and P.N.S. were full-time employees of Idorsia Pharmaceuticals Ltd during the conduct of the study. A.H. and M.T.K. were employees of Clinical Research Services Kiel GmbH and Biokinetica S.A., respectively, during the conduct of the study. Both Clinical Research Services Kiel GmbH and Biokinetica S.A. received financial compensation for the clinical conduct.